fbpx Skip to main content

A retrospective analysis of overall survival for patients with Hodgkin’s Lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and primary central nervous system lymphoma (PCNS) will be presented at the 2021 ASH Annual Meeting & Exposition. This study, published in Blood, is the first large-scale population analysis on a specific state (Texas) to have examined the impact of ethnicity and insurance status on HL, DLBCL, and PCNS survival rates.

Using the Texas Cancer Registry, the researchers identified over 21,000 patients with HL, DLBCL, or PCNS between 2006 and 2017. Data were organized by Hispanic/non-Hispanic ethnicity and insured/uninsured status. The researchers analyzed the survival times of these groups, measured from the day the patient was diagnosed to the date of their last follow-up or death.

Ultimately, the HL, DLBCL, and PCNS overall survival data of the uninsured patients were found to be significantly better than those of the insured patients. When looking specifically at HL, the group with the best overall survival was the uninsured Hispanic patients.

The researchers concluded that insurance status is no longer a determining factor in the overall survival of patients with HL, DLBCL, and PCNS. These results might be due to several factors, including standardized treatment, immediate healthcare enrollment after diagnosis, community healthcare practices, health behaviors, environmental exposure, and genetic predisposition.

This study is important because it furthers the knowledge on insurance status and lymphoma overall survival rates among Americans in general and Hispanic Americans in particular [1].

Source:

[1] Velez-Mejia, C., Liu, Q., Michalek, J. E., & Diaz Duque, A. E. (2021). Insurance is no longer a determinant to improve overall survival for patients diagnosed with HL, DLBCL or PCNS in an enriched Hispanic community. Blood, 138(Supplement 1), 1974. https://doi.org/10.1182/blood-2021-151816

Share this article
You May Also Like::  Can Biosimilars help in implementing a value-based care approach in hematology-oncology?